MORPHOLOGICAL CHANGES IN THE INTERSTITIAL LUNG TISSUE IN RESPONSE TO PARENTERAL ADMINISTRATION SILICA NANOPARTICLES

We analyzed pathomorphologic changes of lung interstitium tissue in male Wistar rats (average weight 250300 g, n=20) after single-pass intravenous administration 1ml (2 mg/ml) 13±2 nm silicon dioxide spherical shape nanoparticles. We estimated tissue reaction on 21 st and 60th days after injection. Diffuse infiltration of alveolar partitions increase was noticed (p <0,05); mast cells and eosinocytes pool increase was not significant. We did not revealed granulomas formation or pneumofibrosis. The revealed changes let us to suppose persistence of dispersible silica dioxide nanoparticles in lung interstitium on all terms of study. Cell reaction trends let us to propose that in lungs nanoparticles distribute with local interstitial macrophages.

диоксид кремния, Si02, наночастицы 12-16 нм, биораспределение, хроническая in vivo токсичность, поражение легких, макрофаги, тучные клетки, эозинофилы, silicon dioxide, SiO2, 12-16 nm nanoparticles, chronic toxicity in vivo, lesion of lung, macrophages, mast cells

1. Matoba T, Egashira K. Nanoparticle-mediated drug delivery system for cardiovascular disease. Int Heart J. 2014; 55(4):281-286.

2. Sundar D.S, Antoniraj M.G, Kumar C.S, Mohapatra S.S, Houreld N.N, Ruckmani K. Recent Trends of Biocompatible and Biodegradable Nanoparticles in Drug Delivery: A Review. Curr Med Chem. 2016. [Epub ahead of print].

3. Trevaskis N.L, Kaminskas L.M, Porter C.J. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015;14(11):781-803.

4. Fang C.L, Wen C.J, Aljuffali I.A, Sung C.T, Huang C.L, Fang J.Y. Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury: An animal study. J Control Release. 2015;213:69-78.

5. Braakhuis H.M, Park M.V, Gosens I, De Jong W.H, Cassee F.R. Physicochemical characteristics of nanomaterials that affect pulmonary inflammation. Particle and Fibre Toxicology. 2014;11:18.

6. Yoshiura Y, Izumi H, Oyabu T. Pulmonary toxicity of well-dispersed titanium dioxide nanoparticles following intratracheal instillation. Journal of Nanoparticle Research. 2015;17(6):241.

7. Zhuravskii S, Yukina G, Kulikova О, Panevin А, Tomson V, Korolev D, Galagudza M. Mast cell accumulation precedes tissue fibrosis induced by intravenously administered amorphous silica nanoparticles. Toxicology mechanisms and methods. 2016; 4: 260-269.

8. Ivanov S, Zhuravsky S, Yukina G, Tomson V, Korolev D, Galagudza M. In vivo toxicity of intravenously administered silica and silicon nanoparticles. Materials. 2012; 5(10): 1873-1889.

9. Yu Y, Li Y, Wang W, et al. Acute Toxicity of Amorphous Silica Nanoparticles in Intravenously Exposed ICR Mice. Xu B, ed. PLoS ONE. 2013;8(4): e61346.

10. Menter D.G, Patterson S.L, Logsdon C.D, Kopetz S, Sood A.K, Hawk E.T. Convergence of Nanotechnology and Cancer Prevention: Are We There Yet? Cancer prevention research (Philadelphia, Pa). 2014; 7(10): 973-992.

11. Carlander U, Li D, Jolliet O, Emond C, Johanson G. Toward a general physiologically-based pharmacokinetic model for intravenously injected nanoparticles. Int. J. Nanomedicine. 2016;11:625-40.